A Critical Review of Biological Properties, Delivery Systems and Analytical/Bioanalytical Methods for Determination of Bevacizumab

Bevacizumab is a chimeric monoclonal human-murine antibody originated from murine monoclonal antibody (muMAb A4.6.1) with the human immunoglobulin IgG1. BVZ binds the extracellular portion of vascular endothelial growth factor receptors (VEGFR), which have tyrosine kinase activity. The mechanism of...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in analytical chemistry 2021, Vol.51 (5), p.445-453
Main Authors: Filippo, Leonardo Delello Di, dos Santos, Karen Cristina, Hanck-Silva, Gilmar, de Lima, Felipe Tita, Gremião, Maria Palmira Daflon, Chorilli, Marlus
Format: Article
Language:English
Subjects:
Analytical methods
Bevacizumab
Biological properties
Chromatography
Cytoplasm
delivery systems
Drug delivery
Drug delivery systems
Enzyme-linked immunosorbent assay
Growth factor receptors
Growth factors
High performance liquid chromatography
Immunoglobulin G
Kinases
Liquid chromatography
Mass spectrometry
Mass spectroscopy
Mathematical analysis
Monoclonal antibodies
Nanostructure
Protein-tyrosine kinase
Qualitative analysis
Receptors
Reliability analysis
Systems analysis
Tyrosine
Vascular endothelial growth factor
Vascular endothelial growth factor receptor 2
Vascular endothelial growth factor receptors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bevacizumab is a chimeric monoclonal human-murine antibody originated from murine monoclonal antibody (muMAb A4.6.1) with the human immunoglobulin IgG1. BVZ binds the extracellular portion of vascular endothelial growth factor receptors (VEGFR), which have tyrosine kinase activity. The mechanism of action of BVZ involves binding to VEGFR, Flt-1 (VEGFR-1) and KDR/Flk-1 (VEGFR-2), inducing homodimerization of two receptor subunits, and, consequently, autophosphorylation of their tyrosine kinase domains located inside the cytoplasm. With the advent of nanostructured systems it is increasingly necessary to look for safe analytical methods, ensuring the reliability of the results obtained by them, becoming essential to ensure the quality of medicines. In this work, the incorporation of bevacizumab in to different drug delivery systems was presented. Moreover, detailed investigation was performed about methods for qualitative and quantitative analyses of bevacizumab, including, biological fluids, and drug delivery systems, were investigated. Most recently high performance liquid chromatography coupled with various detectors, liquid chromatography, mass spectrometry and ELISA were used for this purpose. Thus, this review was performed to evaluate the benefits of bevacizumab carried by nanostructured systems and the analytical methods available for detection and quantification of these drugs.
ISSN:1040-8347
1547-6510
DOI:10.1080/10408347.2020.1743641